Physician profile
Alexia Moutsatsos
NPI 1811024631
$8,274.07
in general payments reported to CMS, 2019-2025
40 companies · $1,575 in 2025
The $1,575 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,385 · 2020: $363 · 2021: $467 · 2022: $952 · 2023: $1,592 · 2024: $1,941 · 2025: $1,575.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,106.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,027.01 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $887.05 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $814.97 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $756.45 | 2021-2025 | |
| Lilly USA, LLC | $598.21 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $590.39 | 2019-2025 | Repatha, Otezla, Repatha |
| Astellas Pharma US INC | $536.20 | 2019-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $440.17 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $311.60 | 2019-2025 | Jardiance |
| Abbott Laboratories | $225.75 | 2021-2024 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $195.90 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $176.86 | 2023-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $155.12 | 2019-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $142.43 | 2019-2025 | Gardasil 9, Gardasil, Verquvo |
| Janssen Pharmaceuticals, INC | $137.08 | 2019 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexia Moutsatsos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.